Lifescience Global




EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence - Pages 102-107

Kenichi Suda1,2, Simon Ito1, Hiroshi Mizuuchi1,2, Yoshihiko Maehara2, Yasushi Yatabe3 and Tetsuya Mitsudomi1,4

Departments of 1Thoracic Surgery, 3Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, 1-1 Kanokoden, Chikusa-ku, Nagoya; 2Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka; 4Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama, Japan





  • Additional Information

    Abstract: It is indisputable that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) prolong progression-free survival in non-small-cell lung cancer (NSCLC) patients with EGFR mutations better than cytotoxic chemotherapy. However, it is unclear whether EGFR-TKIs prolong the overall survival of NSCLC patients, especially in those with postsurgical recurrence.We retrospectively examined 304 NSCLC patients with known EGFR mutational status (excluding those with squamous cell carcinoma), who had undergone pulmonary resection and experienced postsurgical recurrence. Of these patients, 137 carried EGFR mutations and 167 did not. Of the 137 patients with EGFR mutations, 83 were treated with EGFR-TKIs for their recurrent disease, and 32 of the 167 patients without EGFR mutations were treated with EGFR-TKIs. Postsurgical survival was divided into two parts: recurrence-free survival (RFS) and postrecurrence survival (PRS), and these were compared between the subgroups with a multivariate analysis, adjusted for baseline clinical characteristics.There was no significant difference in RFS between patients with EGFR mutations and those without (P = 0.88). PRS was also similar in these two subgroups when we excluded patients who had been treated with EGFR-TKIs (P = 0.64). In patients with EGFR mutations, PRS was significantly longer in those who were treated with EGFR-TKIs than in those who were not given EGFR-TKIs (P = 0.04). However, among patients without EGFR mutations, PRS was similar in patients who had and had not been treated with EGFR-TKIs (P = 0.87). In conclusion, among NSCLC patients with postsurgical recurrence, EGFR-TKIs prolonged PRS in those with EGFR mutations.

    Keywords: Molecular target therapy, biomarker analysis, prognostic factor, predictive factor, gefitinib, erlotinib, pulmonary resection, postsurgical recurrence-free survival (RFS), postrecurrence survival (PRS).


    ♦  Worldwide readership
    ♦  High quality content
    ♦  Maximum visibility
    ♦  Efficient publishing
    ♦  Optional Open Access

    Publish your Research


    As an author what type of publishing model you prefer?

    Open Access
    Optional Open Access
    Subscription based
    5 Votes left